1. Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. (17th April 2022) Authors: Rachedi, Fatiha; Koiwai, Kimiko; Gaudel‐Dedieu, Nadia; Sebastien, Bernard; Thai, Hoai‐Thu; Brillac, Claire; Fau, Jean Baptiste; Nguyen, Laurent; van de Velde, Helgi; Veyrat‐Follet, Christine; Semiond, Dorothée Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 11:Number 6(2022) Page Start: 766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone. Issue 5 (26th November 2021) Authors: Thai, Hoai‐Thu; Gaudel, Nadia; Cerou, Marc; Ayral, Geraldine; Fau, Jean‐Baptiste; Sebastien, Bernard; van de Velde, Helgi; Semiond, Dorothée; Veyrat‐Follet, Christine Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 5(2022) Page Start: 2052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma. (8th July 2021) Authors: Koiwai, Kimiko; El‐Cheikh, Raouf; Thai, Hoai‐Thu; Brillac, Claire; Fau, Jean‐Baptiste; Veyrat‐Follet, Christine; Risse, Marie‐Laure; van de Velde, Helgi; Semiond, Dorothée; Nguyen, Laurent Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 10:Number 8(2021) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗